Tarsus Pharmaceuticals, Inc. (TARS) Misses Q2 EPS by 10c

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q2 EPS of ($0.48), $0.10 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $102.7 million versus the consensus estimate of $95.68 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.

You May Also Be Interested In

• Zhipu AI prices HK offering at HK$1,588/share - Reuters
• BMO Capital Starts Lexington Realty Trust (LXP) at Outperform
• King Slide Works Co Ltd (2059:TT) PT Raised to NT$12,000 at Goldman Sachs